Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - fingolimod hydrochloride 0.56mg;  ;  ;   - capsule - 0.5 mg - active: fingolimod hydrochloride 0.56mg       excipient: capsugel white 4998 gelatin ink iron oxide yellow magnesium stearate mannitol titanium dioxide - gilenya is indicated as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - powder for injection - 10,000ku - active: asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - treatment of acute lymphoblastic leukaemia

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - baclofen 2 mg/ml - solution for injection - 10 mg/5ml - active: baclofen 2 mg/ml excipient: nitrogen sodium chloride water for injection - indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

amgen new zealand limited - pegfilgrastim 10 mg/ml;   - solution for injection - 6 mg/0.6ml - active: pegfilgrastim 10 mg/ml   excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 600 µg/ml;   - solution for injection - 300 mcg/0.5ml - active: filgrastim 600 µg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 300 µg/ml;   - solution for injection - 300 mcg/ml - active: filgrastim 300 µg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

amgen new zealand limited - filgrastim 960 µg/ml (480 µg/syringe);   - solution for injection - 480 mcg/0.5ml - active: filgrastim 960 µg/ml (480 µg/syringe)   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sorbitol water for injection - neupogen is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia and its clinical sequelae in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of neupogen are similar in adults and children receiving cytotoxic chemotherapy. neupogen is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 10^9/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 120mg - modified release tablet - 120 mg - active: oxycodone hydrochloride 120mg excipient: ammonio methacrylate copolymer lactose monohydrate magnesium stearate opadry purple 15b20201 povidone purified talc purified water stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 15mg equivalent to 13.5 mg oxycodone base - modified release tablet - 15 mg - active: oxycodone hydrochloride 15mg equivalent to 13.5 mg oxycodone base excipient: lactose monohydrate magnesium stearate methacrylic acid copolymer opadry grey 05b97512 povidone purified talc stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia